Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 22, 2023
Discovery & Translation
SIGLEC9 inhibition for glioblastoma; plus Long COVID genetic risks and more
BioCentury’s roundup of translational innovations
BioCentury | May 12, 2022
Deals
Cullinan gets $275M up front, reshapes deal with Taiho for EGFR program
Three years after sourcing targeted cancer program from Japanese pharma, Cullinan sells back subsidiary while retaining upside
BioCentury | Mar 30, 2022
Discovery & Translation
iPSC-derived NK cell therapies at AACR22
Presentations highlight gene edits and CAR engineering to improve efficacy of NK cell therapies
BioCentury | Apr 3, 2021
Product Development
Digging beyond the headlines at AACR 2021
Next-wave strategies for KRAS and TIGIT, allogeneic and personalized cell therapies, and targeted protein degraders
BioCentury | Jun 11, 2020
Deals
Cullinan adds first-in-class asset in hot NK cell checkpoint space
Via a deal with Avalon, Cullinan forms new single-asset unit with $26M series A to house anti-MICA mAb
BioCentury | Dec 27, 2019
Product Development
Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform
Xyphos’ animal data and focus on its CAR T switch platform paid off with Astellas takeout
BioCentury | Jul 19, 2019
Product Development
Why GammaDelta would do its Takeda build-to-buy all over again
How GammaDelta's 2017 $100 million option deal with Takeda fueled its multi-pronged pipeline strategy
BioCentury | Jun 8, 2018
Tools & Techniques
NK cell check-in
How new NK cell targets could lead to more powerful checkpoint inhibitors
Items per page:
1 - 10 of 17